 SAN DIEGO and TORONTO, March 31, 2022 GLOBE NEWSWIRE -- Aptose Biosciences Inc. Aptose or the Company NASDAQ: APTO, TSX: APS, a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in a panel to discuss new approaches of treating acute myeloid leukemias AML at Canaccord Genuitys 2022 Horizons in Oncology Virtual Conference: 